Risk reduction for software based railway control systems

2012 ◽  
Author(s):  
P.J. Bryan
Keyword(s):  
Risk Reduction ◽  
Control Systems

System On Chip (SOC) ASIC chipset for Smart Actuators in Distributed Propulsion Systems

2016 ◽  
Vol 2016 (HiTEC) ◽  
pp. 000040-000045
Author(s):  
Bhal Tulpule ◽  
Alireza R. Behbahani
Keyword(s):  
High Temperature ◽  
Embedded Systems ◽  
Risk Reduction ◽  
Control Systems ◽  
Real Time ◽  
System On Chip ◽  
Silicon On Insulator ◽  
Design Development ◽  
Sensors And Actuators ◽  
On Chip

Abstract This paper describes the results of the risk reduction testing task recently completed by Embedded Systems LLC under the Air Force SBIR contract {5} titled “Improved Full Authority Digital Engine Control (FADEC) System”. The objective of this program has been to develop a hierarchical, distributed architecture for future propulsion FADEC and aerospace control systems with flexible, scalable and reconfigurable Smart Nodes (SN) built with high temperature capable devices. A key part of this program is the design, development and validation of the System On Chip (SOC) chipset in high temperature (225 Deg. C) SOI (Silicon On Insulator) technology ASIC (Application Specific Integrated Circuit) devices. The SOC chipset designed by Embedded Systems LLC provides the scalability and reconfigurability that enables the Smart Node to interfaces with most sensors and actuators found in FADEC and other aircraft control systems. The analog portion of this 2-chip SOC chipset fabricated by Honeywell using their SOI process is working properly. The digital portion of the SOC chipset, currently implemented in a commercial temperature FPGA (Field Programmable Gate Array), contains important computational functions needed for reconfiguring the SOC and performing complex control functions, such as real time control of an actuator, The risk reduction task was therefore focused on verification and validation of these key functions in a real environment before converting the design into an ASIC. The recent successful demonstration of the real time actuator control capability has minimized the risks and cleared the way for the digital ASIC implementation. The complete high temperature SOC chipset is expected to be available in late 2016.

Developing theory-based risk-reduction interventions for HIV-positive young people with haemophilia

Haemophilia ◽  
2001 ◽  
Vol 7 (1) ◽  
pp. 64-71 ◽  
Author(s):  
J. R. Schultz ◽  
R. B. Butler ◽  
L. Mckernan ◽  
R. Boelsen ◽  
Keyword(s):  
Young People ◽  
Risk Reduction ◽  
Hiv Positive

Cancer Survivors Need CVD Risk Reduction Too

2005 ◽  
Vol 38 (16) ◽  
pp. 38
Author(s):  
MICHELE G. SULLIVAN
Keyword(s):  
Cancer Survivors ◽  
Risk Reduction ◽  
Cvd Risk

PCSK9 inhibition for LDL lowering and beyond – implications for patients with peripheral artery disease

VASA ◽  
2018 ◽  
Vol 47 (3) ◽  
pp. 165-176 ◽  
Author(s):  
Katrin Gebauer ◽  
Holger Reinecke
Keyword(s):  
Cardiovascular Risk ◽  
Risk Reduction ◽  
Ldl Receptor ◽  
Density Lipoprotein ◽  
Past Century ◽  
Pcsk9 Inhibitors ◽  
Cardiovascular Risk Reduction ◽  
Simultaneous Application ◽  
The Past ◽  
Pcsk9 Inhibition

Abstract. Low-density lipoprotein cholesterol (LDL-C) has been proven to be a causal factor of atherosclerosis and, along with other triggers like inflammation, the most frequent reason for peripheral arterial disease. Moreover, a linear correlation between LDL-C concentration and cardiovascular outcome in high-risk patients could be established during the past century. After the development of statins, numerous randomized trials have shown the superiority for LDL-C reduction and hence the decrease in cardiovascular outcomes including mortality. Over the past decades it became evident that more intense LDL-C lowering, by either the use of highly potent statin supplements or by additional cholesterol absorption inhibitor application, accounted for an even more profound cardiovascular risk reduction. Proprotein convertase subtilisin/kexin type 9 (PCSK9), a serin protease with effect on the LDL receptor cycle leading to its degradation and therefore preventing continuing LDL-C clearance from the blood, is the target of a newly developed monoclonal antibody facilitating astounding LDL-C reduction far below to what has been set as target level by recent ESC/EAS guidelines in management of dyslipidaemias. Large randomized outcome trials including subjects with PAD so far have been able to prove significant and even more intense cardiovascular risk reduction via further LDL-C debasement on top of high-intensity statin medication. Another approach for LDL-C reduction is a silencing interfering RNA muting the translation of PCSK9 intracellularly. Moreover, PCSK9 concentrations are elevated in cells involved in plaque composition, so the potency of intracellular PCSK9 inhibition and therefore prevention or reversal of plaques may provide this mechanism of action on PCSK9 with additional beneficial effects on cells involved in plaque formation. Thus, simultaneous application of statins and PCSK9 inhibitors promise to reduce cardiovascular event burden by both LDL-C reduction and pleiotropic effects of both agents.

Prophylactic Mastectomy - Evaluation and Treatment of High Risk Patients

Swiss Surgery ◽  
2002 ◽  
Vol 8 (2) ◽  
pp. 45-52 ◽  
Author(s):  
Remmel ◽  
Harder
Keyword(s):  
Breast Cancer ◽  
Breast Cancer Risk ◽  
Cancer Risk ◽  
Risk Reduction ◽  
Prophylactic Mastectomy ◽  
Interdisciplinary Approach ◽  
Reconstructive Procedures ◽  
Medline Search ◽  
Breast Cancer Risk Reduction ◽  
Cancer Risk Reduction

Prophylactic mastectomy is an aggressive strategy for breast cancer risk reduction. The indications and efficiency of this procedures are not yet clearly defined. Randomized, prospective studies, comparing different surgical procedures with other modalities of breast cancer risk reduction are lacking. The report evaluates the existing controversy, based on Medline search in the following sequence: risk factors, possibilities of risk reduction, effectiveness of risk reduction, technical considerations and recommendations. Patient selection is difficult and needs an interdisciplinary approach. The women have to be well informed about all treatment alternatives and various reconstructive procedures. An appropriate risk reduction strategy should be selected individually for each patient. Up to now, there exist only recommendations from different institutions but no definitive guidelines.

Sign in / Sign up

Export Citation Format

Share Document